CD8A and hepatocellular carcinoma: In conclusion, our study provides compelling evidence that targeting YAP1 in combination with DDP can significantly enhance the immune response improve the efficacy of chemotherapy in HCC and enhance CD8+T cells in liver cancer tissues.